The Oklahoma Health Care Authority launched an initiative to cure SoonerCare members who have been diagnosed with the hepatitis C virus (HCV).   Mavyret (glecaprevir/pibrentasvir) is now the preferred direct-acting antiviral (DAA) medication for HCV and is available without prior authorization (PA) for SoonerCare members.  Removing the prior authorization allows for easier access to this […]

You are unauthorized to view this page. Please Login or Subscribe